Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Advanced Solid Tumors with Moderate Liver Impairment
NCT04617522Phase 1Recruiting
- Sponsor
- Gilead Sciences
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of sacituzumab govitecan in solid tumor (2 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants experiencing Treatment Emergent Adverse Events and Serious Adverse Events at Day 38, Percentage of Participants Experiencing Any Dose Limiting Toxicities at Day 28 and 4 more. Started Apr 2021; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04617522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617522.